FDA launches mifepristone study after pressure from Trump’s right flank

Published June 5, 2026 11:55am ET | Updated June 5, 2026 2:32pm ET



The Food and Drug Administration has launched a safety review of mifepristone, the drug used for medicated abortions, according to the Wall Street Journal.

The review comes as some anti-abortion advocates have grown increasingly frustrated with the Trump administration, arguing it has moved too slowly on promises to revisit federal abortion pill regulations ahead of the midterm elections.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.